Continuous glucose monitor

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Retrieved on: 
Wednesday, May 8, 2024
Medtech, Telecommunications, PMO, Systems engineering, Health, Embedded system, Diabetes, Himawari (satellites), CGM, Electronic engineering, Innovation, Health care, Continuous glucose monitor, Trinity, Patient, Fortune 500, Acquisition, Harvard Medical School, Savitribai Phule Pune University, Quality of life, Knowledge

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director.

Key Points: 
  • DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director.
  • “We are very excited to welcome Avinash to Trinity Biotech, where he will be instrumental in advancing our mission of introducing intelligent wearable biosensors, including CGMs, into markets all around the globe.
  • Mr. Kale, a seasoned MedTech R&D, PMO & Innovation leader, with extensive global industry experience recently joined Trinity Biotech’s team in Ireland, from Philips Healthcare, The Netherlands.
  • Mr. Kale holds a degree in Electronics and Telecommunications from Pune University, India, and has successfully completed the Leading Digital Transformation in Healthcare Executive Programme from Harvard Medical School.

Global Smart Insulin Pens Market 10 Year Forecast Report 2024-2034 - A USD 2.30 Billion Market by 2034 with a 10% CAGR During 2024-2034

Retrieved on: 
Thursday, March 28, 2024
Diabetes, CGM, Sanofi, Eli Lilly, Prevalence, Dexcom, Data analysis, Incidence, Partnership, Insulin, Patient, Continuous glucose monitor, Prescription, Novo Nordisk, Investment, Research report, USD, Pharmaceutical industry

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.
  • The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034.
  • Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens.
  • Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens.

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024
CGM, Blood, Glucose meter, Treatment, Weight loss, Glycated hemoglobin, Food, Conference, Behavior, Type 2 diabetes, ATTD, Type 2, Smartphone, Patient, Insulin, Heart, Continuous glucose monitor, Appetite, Pharmaceutical industry

These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.

Key Points: 
  • These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.
  • GLP-1 medicines – also known as glucagon-like peptide-1 receptor agonist (GLP-1 RA) - are increasingly being prescribed for people with Type 2 diabetes as they provide glycemic benefit and support weight loss.
  • "While treating my patients, I've observed that when we've added a CGM, like the FreeStyle Libre technology, to their GLP-1 therapy, we see even better glycemic control.
  • To maximize the benefits of GLP-1 medicines, it's worth considering the combination of a CGM to support people who live with Type 2 diabetes."

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Retrieved on: 
Monday, January 8, 2024
Wearables, Mobile Technology, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biotechnology, Health, Continuous glucose monitor, Personal, Multimedia, CGM, Caregiver, DME, AID, Disease, Hyperglycemia, Internet, Tandem Diabetes Care, Control, FreeStyle, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.
  • View the full release here: https://www.businesswire.com/news/home/20240108667517/en/
    t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States.
  • (Photo: Business Wire)
    Tandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute2,3 to the pump.
  • FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump.

$26.89 Bn Wearable Patches Markets - Global and Regional Analysis Report 2023-2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Medical Devices, Health, Technology, Wearables, Mobile Technology, Pharmaceutical, Biotechnology, ECG, Migraine, Nursing, T1D, Abbott Laboratories, Food, Prevalence, Ageing, AID, MDR, Laboratory, Continuous glucose monitor, FDA, Heart rate, Region, CE, Conditional sentence, Clothing, Software, Diagnosis, Communication, Growth, Medicare, Hyperglycemia, FreeStyle, Hospital, Skin, Continuous monitoring, Diabetes, Stroke, GlySens ICGM, Temperature, Hypoglycemia, Blood pressure, Medical device, Pharmaceutical industry

The "Wearable Patches Market - A Global and Regional Analysis: Focus on Usage Type, Application, End User, and Region - Analysis and Forecast, 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wearable Patches Market - A Global and Regional Analysis: Focus on Usage Type, Application, End User, and Region - Analysis and Forecast, 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The key factors driving the growth of the global wearable patches market include continuous monitoring of body vitals and minimum interference with body movement, increasing prevalence of chronic disorders (diabetes, strokes, etc.
  • The top segment players who are leading include manufacturers of different kinds of wearable medical patches.
  • Patches such as blood glucose patches, heart rate and ECG patches, temperature patches, and others are used for monitoring and diagnosis of various conditions.

Global Wearable Patches Market Analysis Report 2023: Market to Exceed $26.8 Billion by 2031 - AI Algorithms for Wearable Patches for Better Clinical Outcome Presents Unique Opportunities

Retrieved on: 
Friday, December 8, 2023
ECG, Migraine, Nursing, T1D, Abbott Laboratories, Food, Prevalence, Ageing, AID, MDR, Laboratory, Stroke, Continuous glucose monitor, FDA, Heart rate, Region, CE, Conditional sentence, Clothing, Diabetes, Software, Diagnosis, Communication, Growth, Medicare, Hyperglycemia, FreeStyle, Hospital, Skin, Continuous monitoring, GlySens ICGM, Temperature, Hypoglycemia, Blood pressure, Beauty salon, Medical device, Pharmaceutical industry

The global wearable patches market was valued at $10,462.4 million in 2022 and is expected to reach $26,892.7 million by 2031, growing at a CAGR of 10.19% between 2023 and 2031.

Key Points: 
  • The global wearable patches market was valued at $10,462.4 million in 2022 and is expected to reach $26,892.7 million by 2031, growing at a CAGR of 10.19% between 2023 and 2031.
  • The top segment players who are leading include manufacturers of different kinds of wearable medical patches.
  • The blood glucose patches captured around 82.23% of the presence in the market in 2022.
  • Patches such as blood glucose patches, heart rate and ECG patches, temperature patches, and others are used for monitoring and diagnosis of various conditions.

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

Retrieved on: 
Tuesday, September 12, 2023
CGM, Diabetes, Continuous glucose monitor, Prediabetes, Patient, Korea Disease Control and Prevention Agency, Architecture, Health, Nemaura Medical, NMRD, Dietary supplement, Medical device

LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .

Key Points: 
  • LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .
  • (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs, today announced it will be participating at the HLTH 2023 conference, in Las Vegas, in October.
  • To support third parties, the Company has made modifications to its architecture to enable sensor integration with other digital programs.
  • This strategy is expected to allow Nemaura to scale its commercialisation programs rapidly and cost-efficiently.

GoodRx Surpasses $500 Million in Savings For Diabetic Americans

Retrieved on: 
Tuesday, August 15, 2023
Software, Pharmaceutical, Internet, General Health, Health, Diabetes, Technology, Apps, Applications, FreeStyle, GoodRx, Prescription, Continuous glucose monitor, Dexcom, Pharmacist, G6, MD, Patient, Physician, Gold, Pharmaceutical industry, Health insurance

While cost is a significant barrier to diabetes patients accessing the care they need, a lack of clear, concise information about treatment plans can be a barrier as well.

Key Points: 
  • While cost is a significant barrier to diabetes patients accessing the care they need, a lack of clear, concise information about treatment plans can be a barrier as well.
  • The GoodRx Health Diabetes Center provides information about treatments, medications, common concerns, and more that is credible and up-to-date to support readers with actionable next steps for managing their condition.
  • “By providing incredible savings and information in one place, GoodRx is an invaluable resource for those living with diabetes to help them more easily access and afford the proper treatment they need.”
    To find savings and trusted health information, download the GoodRx app or go to www.goodrx.com .
  • For even greater savings on your prescriptions, try GoodRx Gold .

One Health Direct Helps Chronic Patients of Their Partner DMEs Reduce Risk of Exposure to Acute Illnesses By Eliminating Unnecessary Trips to Medical Facilities

Retrieved on: 
Wednesday, June 28, 2023
CGM, Learning, OHD, Diabetes, Education, DME, Physician, VOR/DME, Health, Continuous glucose monitor, Patient, Immune system, Durable medical equipment, Roger Hawkins (drummer), Nursing

Avoiding the exposure risks associated with going into clinics and facilities is a major benefit for patients suffering from illnesses that weaken the immune system, such as diabetes.

Key Points: 
  • Avoiding the exposure risks associated with going into clinics and facilities is a major benefit for patients suffering from illnesses that weaken the immune system, such as diabetes.
  • "One Health Direct focuses on the patient, and prioritizes the physician," said Alois Rubenbauer, founder and CEO.
  • The simplified process and support offered by One Health Direct's system eases the stress and burden often put upon patients.
  • Additionally, OHD provides partner DMEs' patients with ongoing support and training which can be accessed from the comfort of their own homes.

Global Insulin Pumps and Continuous Glucose Monitors Market Report 2023: Players Include Medtronic, Abbott Laboratories, DexCom and Insulet - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 21, 2023
Diabetes, Health, Medical Devices, Inclusion, Insulin, Region, Market access, Investment, Country, Continuous glucose monitor, Reading, Medical device, Retail

Key Inclusions of the market model are:

Key Points: 
  • Key Inclusions of the market model are:
    Currently marketed Insulin Pumps and Continuous Glucose Monitors Devices and evolving competitive landscape:
    Granular data on total procedures, units, average selling prices and market values by segment
    Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.
  • In addition publisher analysts provide unique country specific insights on the market
    Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system.
  • In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • This Market Model gives important, expert insight you won't find in any other source.